Experts continue to believe that phosphodiesterase 5 (PDE5) inhibitors, endothelin receptor antagonists with PDE5 inhibitors, and prostanoids are the best therapy for mild cases of PAH [27]. The gene discussed is PDE5A; the disease is pulmonary arterial hypertension.